Establishing The Promise Of Next Generation Sequencing: The Minnesota Guidelines


Unless a coherent and believable evidence base is established it is doubtful that the promise of precision medicine utilizing next generation sequencing (NGS) will be achieved. In common with all too many pharmaceutical products and devices, the initiators and early developers of genomic assay platforms, in particular NGS platforms, have focused on the clinical and scientific performance of assays with investors led to believe that the scientific merits of an assay will lead automatically to reimbursement, formulary acceptance and uptake by treating physicians.

View PDF